Functional and molecular characterization of kinin B1 and B 2 receptors in human bladder cancer: Implication of the PI3Kγ pathway

Investigational New Drugs

Volumn 31, Issue 4, 2013, Pages 812-822

  Sgnaolin, V ^a   Pereira, T C B ^a   Bogo, M R ^a   Zanin, R ^a   Battastini, A M O ^b   Morrone, F B ^a   Campos, M M ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

B1 and B2 receptors; Human biopsies; Kinins; MAP kinases; PI3K ; T24 and RT4 bladder cancer cells

Indexed keywords

G PROTEIN COUPLED RECEPTOR; KININ; KININ B1 RECEPTOR; KININ B2 RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUROPEPTIDE RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; KININ B1 RECEPTOR GENE; KININ B2 RECEPTOR GENE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR GENE; RECEPTOR UPREGULATION; TUMOR BIOPSY;

AGED; AGED, 80 AND OVER; BIOPSY; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, BRADYKININ B1; RECEPTOR, BRADYKININ B2; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84880916726     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9907-6     Document Type: Article

References (51)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277-300
2. Soloway MS, Sofer M, Vaidya A (2002) Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 167:1573-1583
3. Saad A, Hanbury DC, McNicholas TA, Boustead GB, Morgan S, Woodman AC (2002) A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int 89:369-373
4. Sylvester RJ, Van Der MA, Lamm DL (2002) Intravesical bacillus calmette-guerin reduces the risk of progression in patients with superficial bladder cancer: a metaanalysis of the published results of randomized clinical trials. J Urol 168:1964-1970
5. Jordan AM, Weingarten J, Murphy WM (1987) Transitional cell neoplasms of the urinary bladder. Can biologic potential be predicted from histologic grading? Cancer 60:2766-2774
6. Lopez-Beltran A, Cheng L, Mazzucchelli R, Bianconi M, Blanca A, Scarpelli M, Montironi R (2008) Morphological and molecular profiles and pathways in bladder neoplasms. Anticancer Res 28:2893-2900
7. Cheng L, Zhang S, Maclennan GT, Williamson SR, Lopez-Beltran A, Montironi R (2011) Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol 42:455-481
8. Golijanin DJ, Kakiashvili D, Madeb RR, Messing EM, Lerner SP (2006) Chemoprevention of bladder cancer. World J Urol 24:445-472
9. Vineis P, Pirastu R (1997) Aromatic amines and cancer. Cancer Causes Control 8:346-355
10. Jacobs BL, Lee CT, Montie JE (2010) Bladder cancer in 2010: how far have we come? CA Cancer J Clin 60:244-272
11. 1 receptors: new insight sinto their therapeutic potential for the management of inflammation and pain. Trends Pharmacol Sci 27:646-651
12. Regoli D, Barabe J (1980) Pharmacology of bradykinin and related kinins. Pharmacol Rev 32:1-46
13. 1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes. Br J Pharmacol 143:803-818
14. Leeb-Lundberg LM, Marceau F, Müller-Esterl W, Pettibone DJ, Zuraw BL (2005) International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57:27-77
15. Ehrenfeld P, Figueroa CD, Bhoola KD (2011) Kinin: kallikreins and kinins in cancer. In: Bader M, editor. Kinin. De Gruyter. pp. 217-245
16. Mahabeer R, Bhoola KD (2000) Kallikrein and kinin receptor genes. Pharmacol Ther 88:77-89
17. Stewart JM (2003) Bradykinin antagonists as anti-cancer agents. Curr Pharm Des 9:2036-2042
18. Figueroa CD, Ehrenfeld P, Bhoola KD (2012) Kinin receptors as targets for cancer therapy. Expert Opin Ther Targets 16:299-312
19. Bhoola K, Ramsaroop R, Plendl J, Cassim B, Dlamini Z, Naicker S (2001) Kallikrein and kinin receptor expression in inflammation and cancer. Biol Chem 382:77-89
20. 2+ mobilization in MG63 human osteosarcoma cells. Horm Res 55:265-270
21. Ishihara K, Hayash I, Yamashina S, Majima M (2001) A potential role of bradykinin in angiogenesis and growth of S-180 mouse tumors. Jpn J Pharmacol 87:318-326
22. Ishihara K, Kamata M, Hayashi I, Yamashina S, Majima M (2002) Roles of bradykinin in vascular permeability and angiogenesis in solid tumor. Int Immunopharmacol 2:499-509
23. Raidoo DM, Sawant S, Mahabeer R, Bhoola KD (1999) Kinin receptors are expressed in human astrocytic tumour cells. Immunopharmacology 43:255-263
24. Taub JS, Guo R, Leeb-Lundberg LM, Madden JF, Daaka Y (2003) Bradykinin receptor subtype 1 expression and function in prostate cancer. Cancer Res 63:2037-2041
25. 1 receptor antagonist B9958. Int Immunopharmacol 8:289-292
26. 2 receptor and pathological grade in human gliomas. Br J Neurosurg 19:322-326
27. Wu J, Akaike T, Hayashida K, Miyamoto Y, Nakagawa T, Miyakawa K, Müller-Esterl W, Maeda H (2002) Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int J Cancer 98:29-35
28. Stella J, Bavaresco L, Braganhol E, Rockenbach L, Farias PF, Wink MR, Azambuja AA, Barrios CH, Morrone FB, Oliveira-Battastini AM (2010) Differential ectonucleotidase expression in human bladder cancer cell lines. Urol Oncol 28:260-267
29. 1 receptor induces the proliferation of estrogen-sensitive breast cancer cells and activates the ERK 1/2 signaling pathway. Breast Cancer Res Treat 118:499-510
30. 1 receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther 309:661-669
31. 2 receptors in melanoma cells. Peptides 31:238-241
32. Pomel V, Klicic J, Covini D, Church DD, Shaw JP, Roulin K, Burgat-Charvillon F, Valognes D, Camps M, Chabert C, Gillieron C, Françon B, Perrin D, Leroy D, Gretener D, Nichols A, Vitte PA, Carboni S, Rommel C, Schwarz MK, Rückle T (2006) Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. J Med Chem 49:3857-3871
33. Rho HW, Lee BC, Choi ES, Choi IJ, Lee YS, Goh SH (2010) Identification of valid reference genes for gene expression studies of human stomach cancer by reverse transcription-qPCR. BMC Cancer 10:240
34. 2 receptor expression in neutrophils of asthmatic and non-asthmatic subjects. Int Immunopharmacol 7:1862-1868
35. Velarde V, de La Cerda PM, Duarte C, Arancibia F, Abbott E, González A, Moreno F, Jaffa AA (2004) Role of reactive oxygen species in bradykinininduced proliferation of vascular smooth muscle cells. Biol Res 37:419-430
36. 2 bradykinin receptor in epithelial breast cells. J Cell Physiol 201:84-96
37. Lu DY, Tang CH, Yeh WL, Wong KL, Lin CP, Chen YH, Lai CH, Chen YF, Leung YM, Fu WM (2009) SDF-1alpha up-regulates interleukin-6 through CXCR4, PI3K/AKT, ERK, and NF-kappaB-dependent pathway in microglia. Eur J Pharmacol 613:146-154
38. Bhoola KD, Misso N, Naran A, Thompson PJ (2007) Current status of tissue kallikrein inhibitors: importance in cancer. Curr Opin Investig Drugs 8:462-468
39. Stewart JM, Gera L, Chan DC, Bunn PA Jr, York EJ, Simkeviciene V, Helfrich B (2002) Bradykinin-related compounds as new drugs for cancer and inflammation. Can J Physiol Pharmacol 80:275-280
40. Jutras S, Bachvarova M, Keita M, Bascands JP, Mes-Masson AM, Stewart JM, Bachvarov D (2010) Strong cytotoxic effect of the bradykinin antagonist BKM-570 in ovarian cancer cells - analysis of the molecular mechanisms of its antiproliferative action. FEBS J 277:5146-5160
41. Wang YB, Peng C, Liu YH (2007) Low dose of bradykinin selectively increases intracellular calcium in glioma cells. J Neurol Sci 258:44-51
42. Zelawski W, Machnik G, Nowaczyk G, Plewka D, Lorenc Z, Sosada K, Stadnicki A (2006) Expression and localisation of kinin receptors in colorectal polyps. Int Immunopharmacol 6:997-1002
43. Moodley R, Snyman C, Odhav B, Bhoola KD (2005) Visualisation of transforming growth factor-beta 1, tissue kallikrein, and kinin and transforming growth factor-beta receptors on human clear-cell renal carcinoma cells. Biol Chem 386:375-382
44. 1 receptors for kinins. Pharmacol Rev 50:357-386
45. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296:1655-1657
46. Luo J, Manning BD, Cantley LC (2003) Targeting the PI3K-AKT pathway in human cancer: rationale and promise. Cancer Cell 4:257-262
47. Shaw RJ, Cantley LC (2006) Ras, PI3K and mTOR signalling controls tumour cell growth. Nature 25:424-430
48. Spitzenberg V, König C, Ulm S, Marone R, Röpke L, Müller JP, Grün M, Bauer R, Rubio I, Wymann MP, Voigt A, Wetzker R (2010) Targeting PI3K in neuroblastoma. J Cancer Res Clin Oncol 136:1881-1890
49. Knowles MA, Platt FM, Ross RL, Hurst CD (2009) Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev 28:305-316
50. Greco S, Elia MG, Muscella A, Romano S, Storelli C (2005) Bradykinin stimulates cell proliferation through an extracellularregulated kinase 1 and 2-dependent mechanism in breast cancer cells in primary culture. J Endocrinol 186:291-301
51. Greco S, Storelli C, Marsigliante S (2006) Protein kinase C (PKC)-delta/-epsilon mediate the PKC/AKT-dependent phosphorylation of extracellular signal-regulated kinases 1 and 2 in MCF-7 cells stimulated by bradykinin. J Endocrinol 188:79-89